RALEIGH, N.C., Oct. 10 /PRNewswire/ -- Micell Technologies announced today that David E. Kandzari, MD, will present "The Micell Rapid Absorption Polymer DES System" during the Drug-Eluting Stent Summit at the Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, DC, on October 13, 2008. The MiStent(TM), a drug-eluting stent in pre-clinical studies, utilizes a bioresorbable polymer coating that delivers the potential therapeutic benefits of the drug during the healing process. The drug and polymer are both eliminated from the stent within 90 days.
"The Micell DES technology is exciting because it is the first of a new generation of stents being developed to precisely deliver a drug while safely eliminating the polymer faster than any other biodegradable coating that is commercially available," said Kandzari. "The controlled drug release and kinetics enables a lower drug dose while using known and proven polymers and an approved anti-proliferative drug. Taken together, the Micell DES has the potential to offer the therapeutic benefit of a drug-eluting stent and the safety profile of a bare metal stent."
Dr. Kandzari is the Director of Interventional Cardiology Research at the Scripps Clinic in La Jolla, CA.
About Micell Technologies
Micell Technologies is a privately-held, early-stage biomedical company dedicated to applying its unique surface and polymer modification technologies for improved patient benefits for medical device and drug delivery applications. Its first product, MiStent(TM), is a rapid absorbing coated drug-eluting stent (DES) with precise control of drug release and pharmacokinetics. To learn more, please visit our website at http://www.micell.com.
Contact: James McClain Ph.D., Chief Technology Officer
Micell Technologies: (919) 313-2111
|SOURCE Micell Technologies|
Copyright©2008 PR Newswire.
All rights reserved